Malignant melanoma is a highly aggressive skin cancer responsible for 80% of mortality, and the overall median survival in patients with metastatic melanoma is only 6-9 months. Combination treatment through the simultaneous administration of dual drugs in a single nanocarrier has been demonstrated to be elegant and effective in combatting cancer. Herein, we employ a combination therapy based on dacarbazine (DBZ), FDA approved drug for melanoma and all-trans retinoic acid (ATRA), promising anticancer agents loaded on lipid nanoformulations (RD-LNF) as a new treatment strategy for malignant melanoma. We have successfully encapsulated both the drugs in lipid nanoformulations and showed a controlled release of payload over time. We demonstrated that the simultaneous delivery of DBZ and ATRA could effectively reduce cell proliferation in a concentration-dependent manner. The combinational nanoparticles significantly reduced the colony formation ability of B16F10 melanoma cells. Flow cytometer analysis showed that RD-LNF induced a greater proportion of apoptosis cells with significant inhibition of cell cycle progression and cell migration. These results suggest the promising potential of RD-LNF in the treatment of malignant melanoma with high efficacy.

中文翻译：

---

达卡巴嗪和全反式维甲酸（ATRA）的脂质纳米制剂共同递送对恶性黑素瘤的协同抗肿瘤功效。

恶性黑色素瘤是一种高度侵袭性的皮肤癌，其死亡率占80％，而转移性黑色素瘤患者的总体中位生存期仅为6-9个月。通过在单个纳米载体中同时施用双重药物的联合治疗已被证明在对抗癌症方面是优雅而有效的。在本文中，我们采用基于达卡巴嗪（DBZ），FDA批准的黑色素瘤药物和全反式维甲酸（ATRA）的联合疗法，有望将脂质纳米制剂（RD-LNF）上载的抗癌药作为恶性黑色素瘤的新治疗策略。我们已经成功地将这两种药物封装在脂质纳米制剂中，并显示了有效载荷随时间的受控释放。我们证明，DBZ和ATRA的同时递送可以有效地以浓度依赖性方式减少细胞增殖。组合的纳米粒子显着降低了B16F10黑色素瘤细胞的集落形成能力。流式细胞仪分析表明，RD-LNF诱导更大比例的凋亡细胞，并显着抑制细胞周期进程和细胞迁移。这些结果表明，RD-LNF具有治疗恶性黑色素瘤的高潜力的潜力。